The amendment, dated April 11, 2025, introduces provisions allowing each seller to subscribe for Class B ordinary shares of Royalty Pharma plc equal to the number of non-voting Class E ordinary shares of RPH they receive as part of the transaction's aggregate consideration. Sellers will pay a nominal subscription price for these shares, which is due in cash at the closing of the transaction. The company, currently trading at a P/E ratio of 16.27 and offering a dividend yield of 2.82%, has demonstrated consistent shareholder value creation.